Reference(s)
Click here to return to the Reference Table

Category: Hematopoietic Malignancies
Cancer type: Multiple Myeloma
Descriptor: Met expression


Reference Number: 160
Borset, M., Hjorth-Hansen, H., Seidel, C., Sundan, A. & Waage, A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88, 3998-4004 (1996).
PubMed link      E-mail link

Reference Number: 161
Borset, M., Seidel, C., Hjorth-Hansen, H., Waage, A. & Sundan, A. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma 32, 249-56 (1999).
PubMed link      E-mail link

Reference Number: 162
Derksen, P. W. et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17, 764-74. (2003).
PubMed link      E-mail link

Reference Number: 163
Seidel, C., Borset, M., Hjorth-Hansen, H., Sundan, A. & Waage, A. Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Med Oncol 15, 145-53 (1998).
PubMed link      E-mail link

Reference Number: 448
Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 67, 9913-20 (2007)
PubMed link      E-mail link

Reference Number: 811
Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A. c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur J Haematol. 82, 277-87 (2009)
PubMed link      E-mail link

Reference Number: 1118
Wader KF, Fagerli UM, Holt RU, Børset M, Sundan A, Waage A. Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters. Eur J Haematol. 87, 394-9 (2011)
PubMed link      E-mail link

Reference Number: 1138
Wader KF, Fagerli UM, Børset M, Lydersen S, Hov H, Sundan A, Bofin A, Waage A. Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease. Histopathology. 60, 443-51 (2012)
PubMed link      E-mail link

Reference Number: 1156
Que W, Chen J, Chuang M, Jiang D. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS. 120, 195-203 (2012)
PubMed link      E-mail link

Reference Number: 1330
Kristensen IB, Christensen JH, Lyng MB, Møller MB, Pedersen L, Rasmussen LM, Ditzel HJ, Abildgaard N. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Br J Haematol. 161, 373-82 (2013)
PubMed link      E-mail link

Reference Number: 1421
Rocci A1, Gambella M, Aschero S, Baldi I, Trusolino L, Cavallo F, Gay F, Larocca A, Magarotto V, Omedè P, Isaia G, Bertotti A, Liberati AM, Catalano L, De Rosa L, Musto P, Vallone R, Falcone A, Drandi D, Ladetto M, Comoglio PM, Boccadoro M, Palumbo A. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. Br J Haematol. 164, 841-50 (2014)
PubMed link      E-mail link

Reference Number: 1430
Moschetta M1, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R, Solimando AG, Giuliani N, Boccarelli A, Fumarola F, Coluccia M, Rossini B, Ruggieri S, Nico B, Maiorano E, Ribatti D, Roccaro AM, Vacca A. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin Cancer Res. 19, 4371-82 (2013)
PubMed link      E-mail link

Reference Number: 1533
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 6, 92 (2013)
PubMed link      E-mail link

Reference Number: 1653
Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando AG, Vergara D, Maffia M, Latorre D, Rizzello A, Zito A, Ditonno P, Maiorano E, Ribatti D, Vacca A. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. Clin Cancer Res. 20, 5796-807 (2014)
PubMed link      E-mail link